OREANDA-NEWS. January 28, 2011. JSC "Grindeks" informs that the company successfully continues registration of Mildronate® in the People's Republic of China.

Last week in China, Beijing "Grindeks" management representatives - Chairman of the Council Kirovs Lipmans, R&D Director Nilss Poritis and Head of Regulatory Affairs Department Linda Litina met with the management of China's State Food and Drug Agency, as well as medication registration and research specialists. The visit was also attended by Latvia's Ambassador to the People's Republic of China Ingrida Levrence and other representatives of the embassy.

During the meeting, the registration process of Mildronate® was discussed, paying particular attention to the report on pharmacokinetics of the clinical trial of Mildronate®.

Chairman of the Council of JSC "Grindeks" Kirovs Lipmans: "Mildronate® is the original product of "Grindeks", with which we are purposefully going to enter the highly promising Chinese market. During the meeting, Chinese State Food and Drug Agency's management confirmed that "Grindeks" has fulfilled all the preconditions to open Mildronate® clinical trial. It is planned that in the near future "Grindeks" will start cooperation with several clinical research centers in China."

Mildronate® is the main original product of "Grindeks", and its main sales markets are Russia and other CIS countries. In 2010 an international clinical trial on the influence of the original product Mildronate® on the treatment of angina was successfully finished. "Grindeks" altogether invested 1.6 million lats in this research.

To reduce the dominance of one product "Grindeks" has significantly increased turnover amount of other medications and active pharmaceutical ingredients in the product portfolio over the past years. Mildronate® proportion has fallen from 73% to 51%.